COMPANY

Innovative Bio Venture developing a new concept of cell therapy

Digital Catalog

Since 2018.
2018 History
SCI Paper & IP
78 R&D Excellence
Equipment
27 R&D Competitiveness

Entr®
(Ultrasound-directed permeation of Environmental transition-guided cellular reprogramming)

Cell reprogramming induction technology of a new paradigm using only ultrasound and environmental control factors

Digital Cell Reprogramming

Automation system for Entr-based cell reprogramming induction

Reprosome®
(A cocktail of reprogramming factors in the exosomes )

Customized exosome containing various cell reprogramming factors induced from human fibroblasts with Entr technology, a core technology of STEMON.

Pipeline

Development of treatments for various intractable diseases using customized Reprosomes induced based on Entr technology

R&D

Research and development
of treatments for
intractable diseases

  • Entr®

  • Digital Cell Reprogramming

  • Reprosome®

  • Pipeline

NEWS

STEMON is adding values
to mankind with the best technology.

Full View
News

STEMON at SPOGA HORSE 2026 with Repropet®

STEMON Inc. participated in SPOGA HORSE 2026, held February 7–9 at Koelnmesse in Cologne, Germany, where the company showcased its advanced exosome-based technology for veterinary wound care.During the exhibition, STEMON highlighted STMD-02 (Repropet®), an innovative wound care solution for animals designed to support enhanced healing and tissue regeneration. Clinical case examples presented at the booth demonstrated effective control of inflammation, stabilization of the wound environment, and improved tissue regeneration, underscoring the growing potential of exosome-based therapy in veterinary applications.The event provided a valuable opportunity to connect with professionals across equine care, veterinary medicine, animal health, and biotechnology. Building on the meaningful discussions and industry interest received at SPOGA HORSE, STEMON looks forward to expanding global collaborations and continuing to advance regenerative exosome solutions for animal treatment.

2026.02.13
News

STEMON Participates in COSMEWEEK 2026 in Tokyo

STEMON Inc. showcased its innovative exosome-based digital bio-platform technologies at COSME WEEK TOKYO 2026,engaging with global beauty professionals through insightful and inspiring discussions. During the exhibition, STEMON introduced its latest innovations, including the Plant Color Exosome (VitB12) and Ginseng PDRN Exosomewhich quickly became some of the most discussed highlights at our booth. The strong interest and active engagement around these plant-derived,exosome-based solutions reaffirmed our vision for the future of beauty and skincare. Notably, STEMON recorded one of the highest QR code engagement rates across the entire exhibition and was selected as one of the Top 10 Innovative Ingredientsamong all participating companies, underscoring the industry’s recognition of our technological leadership. Building on the meaningful connections and productive exchanges throughout the event, STEMON looks forward to exploring future collaborationopportunities and further strengthening its global leadership in digital bio-innovation.

2026.01.19
News

STEMON at VIV MEA 2025 with Repropet®!

​STEMON Inc. participated in VIV MEA 2025, held in Abu Dhabi in November 2025, where the company showcased its premium medical device–grade exosome technology for advanced veterinary wound care. At the exhibition, STEMON unveiled Repropet®, a next-generation wound care solution for pets powered by Reprosome®, a high-purity, exosome platform produced through digital reprogramming. The innovative product drew significant interest as a regenerative, science-driven approach to veterinary wound management. As a bio-platform company developing therapeutics for intractable diseases, medical devices, and research-grade exosomes, STEMON will continue expanding global partnerships and advancing digital exosome innovation through its proprietary automated induction system, UltraRepro®.

2025.12.08
News

STEMON Participates in COSMOPROF 2025 in Hong Kong

STEMON Inc. showcased its innovative exosome-based digital bio-platform technologies at COSMOPROF HONG KONG 2025, engaging with global visitors through insightful and inspiring discussions. During the exhibition, STEMON presented UltraRepro®, its automated exosome induction platform, and DDDS®, its digital exosome drug-loading automation system, setting new standards in digitalized biotechnology and gaining strong interest across the cosmetics, medical device, and advanced therapeutic sectors. Building on the meaningful connections made throughout the event, STEMON looks forward to exploring future collaboration opportunities and further strengthening its global leadership in digital bio-innovation.

2025.12.08
STEMON Exosome Platform-Based Portfolio